^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Jaypirca (pirtobrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    12/01/2023
    Excerpt:
    JAYPIRCA is a kinase inhibitor indicated for the treatment of...Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    06/12/2023
    Excerpt:
    CLL/SLL without del(17p)/TP53 mutation….Second-line or Third-line Therapy: Useful in certain circumstances regimen...Pirtobrutinib (resistance or intolerance to prior covalent BTKi therapy). Therapy for Relapsed or Refractory Disease After Prior BTKi-and Venetoclax-Based Regimens: other recommended regimen...Pirtobrutinib (if not previously used).